A Real-World Observational Analysis Comparing the Effectiveness and Safety of Treatment with Apixaban Versus Other Oral Anticoagulants Among Elderly Non-valvular Atrial Fibrillation Patients.
Phase of Trial: Phase IV
Latest Information Update: 15 Nov 2017
Price : $35 *
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban; Warfarin
- Indications Embolism; Stroke
- Focus Adverse reactions; Therapeutic Use
- 15 Nov 2017 Results (n=57025) presented at the 90th Annual Scientific Sessions of the American Heart Association.
- 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
- 10 Nov 2017 According to Bristol-Myers Squibb media release, data will be presented at 2017 American Heart Association (AHA) Scientific Sessions.